


# 2019 Novel Coronavirus (COVID-19)

South Dakota Department of Health

October 14th, 2021



**We will begin in just a few moments. Thanks!**

*Not intended for press or for reporting purposes.*



SOUTH DAKOTA DEPARTMENT OF HEALTH

This is an **emerging, rapidly evolving situation**. Information in this presentation is current as of October 13th, 2021. Please check the South Dakota Department of Health website for the most current information and guidance.

**[COVID.sd.gov](https://COVID.sd.gov)**


*Not intended for press or for reporting purposes.*




SOUTH DAKOTA DEPARTMENT OF HEALTH

# COVID-19 Case Forecast

## National Forecast




## SD Forecast



<https://www.cdc.gov/coronavirus/2019-ncov/science/forecasting/forecasts-cases.html>

*Graphs not on the same scale.*

# Pregnant people with laboratory-confirmed SARS-CoV-2 infection (National COVID-19 Case Surveillance Data)\*




National COVID-19 case surveillance data: Pregnant people with laboratory-confirmed SARS-CoV-2 infection,\* Jan 22, 2020–Sep 13, 2021

\* Based on detection of SARS-CoV-2 in a clinical specimen by molecular amplification techniques


<https://covid.cdc.gov/covid-data-tracker/#pregnant-population>

# COVID-19 cases, ICU admission and death among pregnant people (National COVID-19 Case Surveillance Data; Jan 22, 2020 – Sep 13, 2021)




# Severe illness and adverse maternal, pregnancy, and neonatal outcomes among pregnant women with COVID-19

Compared with non-pregnant WRA\* with COVID-19



Compared with pregnant women without COVID-19





# Growing evidence on safety and effectiveness of COVID-19 vaccination during pregnancy

- Preliminary findings on safety are reassuring
  - Early data did not find any vaccine-related safety concerns for pregnant people vaccinated in the third trimester or for their babies.
  - No increased risk of miscarriage among pregnant people vaccinated before 20 weeks
- Early data suggest mRNA COVID-19 vaccines during pregnancy are effective
- Maternal antibodies following COVID-19 vaccination during pregnancy were present in umbilical cord blood



[Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons | NEJM](https://jamanetwork.com/journals/jama/fullarticle/2782047)  
<https://jamanetwork.com/journals/jama/fullarticle/2782047>  
[Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study - American Journal of Obstetrics & Gynecology \(ajog.org\)](https://ajog.org/)

# Updated clinical considerations: COVID-19 vaccination during pregnancy and lactation

- COVID-19 vaccination is recommended for all people aged 12 years and older, **including people who are pregnant, breastfeeding, or who trying to get pregnant now or might become pregnant in the future.**
- Consistent with recommendations from professional medical organizations





# Summary: Evidence indicates benefits of COVID-19 vaccination during pregnancy outweigh potential risks



Pregnancy increases the risk for severe illness and death from COVID-19 and COVID-19 is associated with adverse maternal, pregnancy and neonatal outcomes

Data on the safety of receiving mRNA COVID-19 vaccine during pregnancy are reassuring


Receipt of an mRNA COVID-19 vaccine during pregnancy reduces the risk for infection

Vaccination during pregnancy results in antibodies that have been detected in infant cord blood


Vaccination coverage for pregnant people is low

# COVID-19 vaccination coverage among pregnant people

Percent of pregnant people aged 18–49 years fully vaccinated with COVID-19 vaccine prior to and during pregnancy, by timing of vaccination and date reported to CDC—Vaccine Safety Datalink, United States, December 14, 2020–October 2, 2021



# Health Alert Notice Urging Vaccination among Pregnant People



<https://emergency.cdc.gov/han/2021/han00453.asp>

## **COVID-19 Vaccination for Pregnant People to Prevent Serious Illness, Deaths, and Adverse Pregnancy Outcomes from COVID-19**

The Centers for Disease Control and Prevention (CDC) recommends urgent action to increase Coronavirus Disease 2019 (COVID-19) vaccination among people who are pregnant, recently pregnant (including those who are lactating), who are trying to become pregnant now, or who might become pregnant in the future. CDC **strongly recommends** COVID-19 vaccination either before or during pregnancy because the benefits of vaccination outweigh known or potential risks.

# COVID-19 Dashboard Update – Vaccine Tab

Total Doses  
Administered\*

847,046

Total Persons Administered a  
Vaccine\*

439,713

Percent of State  
Population with at least  
1 Dose\*\*

66%

Manufacturer	# of Doses
Janssen	29,451
Moderna	336,569
Pfizer	481,026

Doses	# of Recipients
Janssen - Series Complete	29,451
Moderna - 1 dose	10,908
Moderna - Series Complete	158,593
Moderna - 3rd dose	2,800
Pfizer - 1 dose	19,867
Pfizer - Series Complete	194,022
Pfizer - 3rd/Booster dose	24,348

Doses	% of Pop.
1 dose	65.79%
Series Complete	56.86%

*Based on 2019 Census Estimate for those  
aged 12+ years.*

<https://doh.sd.gov/COVID/Dashboard.aspx>



SOUTH DAKOTA DEPARTMENT OF HEALTH

# Agenda

- Situation Update
- Laboratory Guidance
- Long Term Care
- Vaccination Update
- Infection Prevention
- Community Mitigation
- Supply Chain Management
- On-going Communications
- Q&A Session

*Not intended for press or for reporting purposes.*



SOUTH DAKOTA DEPARTMENT OF HEALTH

# Coronavirus Situation


- [International](#)
  - 238,229,951 confirmed cases
    - 4,859,277 deaths
- [United States](#) (50 states + DC)
  - 44,194,808 confirmed cases
    - 710,757 deaths
- [South Dakota](#)
  - 148,249 confirmed and probable cases
    - 2,177 deaths
    - 139,533 recovered cases





# Epidemiologic “Epi” Curve of COVID-19 Cases, by Date Reported to SD-DOH


Cases by Date Reported to SD-DOH



As of October 12th, 2021

*Not intended for press or for reporting purposes.*

# COVID-19 Case Map, by County



Community Spread	Number of Counties
Low	1
Moderate	3
Substantial	8
High	54


As of October 12th, 2021

*Not intended for press or for reporting purposes.*



SOUTH DAKOTA DEPARTMENT OF HEALTH

# At least 1 Dose COVID-19 Vaccine, Coverage Rate by Age Group, SD



As of October 12th, 2021

*Not intended for press or for reporting purposes.*

# General Testing Recommendations

Medical providers are recommended to test individuals (1) identified as a close contact to a person with COVID-19 or (2) signs and symptoms compatible with COVID-19 infection, including:

- Fever or chills
- Cough
- Shortness of breath or difficulty breathing
- Fatigue
- Muscle or body aches
- Headache
- New loss of taste or smell
- Sore throat
- Congestion or runny nose
- Nausea or vomiting
- Diarrhea

<https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>

*Not intended for press or for reporting purposes.*



SOUTH DAKOTA DEPARTMENT OF HEALTH

# Reporting COVID-19 Tests to SD-DOH

- **Reminder:** Coronavirus respiratory syndromes are a Category I disease
- Report **immediately** on suspicion of disease
- Reporting mechanisms:
  - Electronic Laboratory Report (ELR) – HL7 message to SD Health Link (health information exchange)
  - Flat file (CSV) – Secure email
  - Disease reporting website – [sd.gov/diseasereport](https://sd.gov/diseasereport)
    - Ensure patient phone numbers are included
  - Fax – 605.773.5509

*Not intended for press or for reporting purposes.*



SOUTH DAKOTA DEPARTMENT OF HEALTH

# Breakthrough, Variant, and Reinfection Cases

Breakthrough Cases	#
Cases	3,958
Hospitalized	257
Died	41

Variant Cases	#
Cases	557
Hospitalized	30
Died	7


Reinfection	#
Cases	923
Hospitalized	50
Died	13

COVID-19 Variant Data under *Tables* tab:  
<https://doh.sd.gov/COVID/Dashboard.aspx>



# Cases, Hospitalizations, and Deaths by Age Group

## Cumulative




Pct of Cases (distribution of cases across age groups)  
Pct Hospitalized (of cases within age groups)  
Pct Died (of cases within age groups)

Age Range

# Cases, Hospitalizations, and Deaths by Age Group

## June 1st, 2021 to October 8th, 2021



Percentage of Cases	9.89%	14.22%	16.12%	16.66%	12.65%	11.27%	10.47%	5.81%	2.91%
Percentage of Hospitalizations	2.11%	1.05%	6.58%	9.04%	11.58%	15.09%	20.18%	18.16%	16.23%
Percentage of Deaths	0.00%	0.00%	0.77%	6.92%	6.15%	16.15%	23.85%	21.54%	24.62%


Pct of Cases (distribution of cases across age groups)  
Pct Hospitalized (of cases within age groups)  
Pct Died (of cases within age groups)

As of October 8th, 2021

*Not intended for press or for reporting purposes.*

# Pediatric COVID-19 Cases in Counties With and Without School Mask Requirements — United States, July 1–September 4, 2021

FIGURE. Mean county-level change in daily number of COVID-19 cases per 100,000 children and adolescents aged <18 years in counties (N = 520) with and without school mask requirements\* before and after the start of the 2021–22 school year — United States, July 1–September 4, 2021



\* Among 520 counties, 198 (38%) had a school mask requirement and 322 (62%) did not have a school mask requirement.

# Comparative Effectiveness of Moderna, Pfizer, and Janssen Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March–August 2021

**TABLE 2. COVID-19 vaccine effectiveness\* against COVID-19–associated hospitalization among adults without immunocompromising conditions, by vaccine product — 21 hospitals in 18 U.S. states,† March–August 2021**

Vaccine/Period	Vaccinated patients/Total patients (%)		VE against COVID-19 hospitalization (95% CI)
	Case-patients	Control-patients	
<b>Moderna VE after full vaccination</b>			
Full surveillance period <sup>§</sup>	54/1,517 (3.6)	422/1,321 (31.9)	93 (91–95)
14–120 days after full vaccination	36/1,499 (2.4)	345/1,244 (27.7)	93 (90–95)
>120 days after full vaccination	18/1,481 (1.2)	77/976 (7.9)	92 (87–96)
<b>Pfizer-BioNTech VE after full vaccination</b>			
Full surveillance period	128/1,591 (8.0)	610/1,509 (40.4)	88 (85–91)
14–120 days after full vaccination	65/1,528 (4.3)	495/1,394 (35.5)	91 (88–93)
>120 days after full vaccination	63/1,526 (4.1)	115/1,014 (11.3)	77 (67–84)
<b>Janssen (Johnson &amp; Johnson) VE after full vaccination</b>			
Full surveillance period	37/1,500 (2.5)	76/975 (7.8)	71 (56–81)
>28 days after full vaccination	33/1,496 (2.2)	59/958 (6.2)	68 (49–80)

**Abbreviations:** CI = confidence interval; VE = vaccine effectiveness.

# Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021


TABLE. COVID-19 vaccine effectiveness\* against laboratory-confirmed COVID-19–associated emergency department and urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance, by outcome, age group, and vaccine — nine states†, June–August 2021

Outcome	Total	No. of SARS-CoV-2 positive tests (row %)	VE, % (95% CI)
COVID-19 hospitalizations by COVID-19 vaccine			
BNT162b2 (Pfizer-BioNTech)			
Unvaccinated (ref )	6,960	1,316 (18.9)	—
Fully vaccinated**	4,243	135 (3.2)	80 (73–85)
mRNA-1273 (Moderna)			
Unvaccinated (ref )	6,960	1,316 (18.9)	—
Fully vaccinated**	2,975	70 (2.4)	95 (92–97)
Ad26.COV2.S (Janssen)			
Unvaccinated (ref )	6,960	1,316 (18.9)	—
Fully vaccinated**	458	30 (6.5)	60 (31–77)
COVID-19 ED/UC encounters by COVID-19 vaccine			
BNT162b2 (Pfizer-BioNTech)			
Unvaccinated (ref )	10,872	3,145 (28.9)	—
Fully vaccinated**	3,946	314 (8.0)	77 (74–80)
mRNA-1273 (Moderna)			
Unvaccinated (ref )	10,872	3,145 (28.9)	—
Fully vaccinated**	2,656	98 (3.7)	92 (89–93)
Ad26.COV2.S (Janssen)			
Unvaccinated (ref )	10,872	3,145 (28.9)	—
Fully vaccinated**	757	100 (13.2)	65 (56–72)

**Abbreviations:** CI = confidence interval; ED = emergency department; HHS = U.S. Department of Health and Human Services; Janssen = Johnson & Johnson vaccine; Ref = referent group; UC = urgent care; VE = vaccine effectiveness.

# Safety Monitoring of an Additional Dose of COVID-19 Vaccine — United States, August 12–September 19, 2021

**FIGURE.** Adverse reactions and health impacts reported by persons who received 3 doses\* of Moderna (N = 6,283) or Pfizer-BioNTech (N = 6,308) COVID-19 vaccine and completed at least one v-safe health check-in survey on days 0–7 after each dose, by dose number — United States, August 12–September 19, 2021





# Selected CDC Updates

Available at: <https://www.cdc.gov/coronavirus/2019-ncov/whats-new-all.html>

COVID Data Tracker: <https://covid.cdc.gov/covid-data-tracker/#datatracker-home>

Covid-19 Vaccines for Moderately to Severely Immunocompromised:  
<https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html>

Travel Recommendations by Destination: <https://www.cdc.gov/coronavirus/2019-ncov/travelers/map-and-travel-notice.html>

*Not intended for press or for reporting purposes.*




SOUTH DAKOTA DEPARTMENT OF HEALTH

# Laboratory Guidance



SOUTH DAKOTA DEPARTMENT OF HEALTH

# COVID-19 Tests Reported to SDDOH by Month



## COVID-19 Testing and Supply Chain Updates:

- ✓ Significant demand for testing
- ✓ Some testing supplies remain on allocation
- ✓ Some plastic supplies are backordered
- ✓ Shipping delays are common

## Recommendations:

- ✓ Diversify testing
- ✓ Diversify vendors
- ✓ Order supplies early and often

# Testing Resources Available through SDDOH

- Specimen collection supplies
- Packaging and shipping supplies
- Saliva test kits through Vault Health/Rutgers Laboratory
- Antigen test kits
- For questions about BinaxNOW availability, please contact:
  - Long-term Care: [Denise.Broadbent@state.sd.us](mailto:Denise.Broadbent@state.sd.us)
  - Healthcare: [Laurie.Gregg@state.sd.us](mailto:Laurie.Gregg@state.sd.us)
  - K-12 Schools: [Joe.Moran@state.sd.us](mailto:Joe.Moran@state.sd.us)
  - Higher Education: [Laurie.Gregg@state.sd.us](mailto:Laurie.Gregg@state.sd.us)
  - Childcare Providers: [Laura.Nordbye@state.sd.us](mailto:Laura.Nordbye@state.sd.us)
- Inquiries for BinaxNOW and ID NOW resources can also be sent to: [Dorothy.Ahten@abbott.com](mailto:Dorothy.Ahten@abbott.com)



# SDPHL SARS-CoV-2 Sequencing: Specimen Requests

- With increased testing, laboratories are identifying more cases of COVID-19.
- The SDPHL monthly sequencing goal is 300 specimens.
- SDPHL asks that laboratories send the following SARS-CoV-2-positive specimens each week:
  - Rural clinics, FQHCs, etc: first five (5)
  - Indian Health Services and tribal clinics: first ten (10)
  - Critical access hospital laboratories: first ten (10)
  - Higher-education partners: first ten (10)
  - Large hospital laboratory partners: first twenty-five (25)
  - Reference laboratory partners: first twenty-five (25)
- Nasal or nasopharyngeal swab specimens should be submitted in viral transport medium, sterile saline or sterile PBS within 48 hours of collection.


# COVID-19 Monoclonal Antibody Therapy Availability

- Monoclonal antibodies are now only available by federal allocation through Amerisourcebergen (ASB).
  - Allocation is based on case counts, hospitalizations, and therapy use
  - Monoclonal antibody (mAb) therapies available through ASB include:
    - REGEN-CoV (Regeneron) – intravenous infusion and subcutaneous injection
    - Bamlanivimab/Etesevimab (Ely Lilly) – intravenous infusion only
    - Sotrovimab (GlaxoSmithKline) – intravenous infusion only
      - Added to federal allocation 10/11/21 (Week 5)





# COVID-19 mAb Therapy Distribution and Shipment



# COVID-19 Monoclonal Antibody Therapy Allocation

Allocation Wk (Date)	REGEN-CoV	Bam/Ete	Sotrovimab	Total Courses
Week 1 (9/13)	380	50	-	430
Week 2 (9/20)	336	156	-	492
Week 3 (9/27)	396	170	-	566
Week 4 (10/4)	360	200	-	560
Week 5 (10/11)	216	260	144	620

- **Monoclonal antibody therapy is not a substitute for vaccination!**
- It is strongly recommended that all eligible individuals receive a COVID-19 vaccine.
- Due to high demand, mAb therapy is only recommended for [highest-risk COVID patients](#).
- Questions about mAb therapies and availability can be sent to: [Bob.Coolidge@state.sd.us](mailto:Bob.Coolidge@state.sd.us)



# Long Term Care



SOUTH DAKOTA DEPARTMENT OF HEALTH

# Disease Impact & Vaccine Status in LTC – United States

*as of 10.07.2021. Data reported by nursing homes to the CDC's National Healthcare Safety Network (NHSN) system COVID-19 Long Term Care Facility Module.*

By the numbers

84.6%

National Percent of Vaccinated Residents per Facility

67.1%

National Percent of Vaccinated Staff per Facility

702,285

Total Resident COVID-19 Confirmed Cases

137,126

Total Resident COVID-19 Deaths

650,161

Total Staff COVID-19 Confirmed Cases

2,084

Total Staff COVID-19 Deaths

<https://data.cms.gov/stories/s/COVID-19-Nursing-Home-Data/bkwz-xpvg/>

*This call is not intended for the press or for reporting purposes.*



SOUTH DAKOTA DEPARTMENT OF HEALTH

# Long Term Care in South Dakota

*Trending of Disease in Nursing  
Homes and Assisted Living  
Centers*

- 909 Deaths in LTC residents
- 42% of deaths among people with COVID-19

Week	Resident Cases	Staff Cases	Number of Facilities	Nursing Homes	Assisted Living Centers	Facility Cases in Staff Only
06/07/2021	0	2	2	2	0	2
06/14/2021	1	1	2	2	0	1
06/21/2021	2	0	2	1	1	0
06/28/2021	1	2	3	1	2	2
07/05/2021	0	4	4	3	1	4
07/12/2021	0	2	2	2	0	2
07/19/2021	7	3	2	2	0	1
07/26/2021	14	5	4	4	0	2
08/02/2021	16	15	10	8	2	7
08/09/2021	26	23	15	11	4	9
08/16/2021	25	31	23	15	8	16
08/23/2021	39	45	31	21	10	21
08/30/2021	70	70	38	25	13	25
09/06/2021	83	89	39	27	12	20
09/13/2021	97	102	46	33	13	24
09/20/2021	102	100	46	30	16	24
09/27/2021	86	95	40	28	12	24
10/04/2021	107	101	48	33	15	20
10/11/2021	136	108	50	37	13	24

*This call is not intended for the press or for reporting purposes.*



SOUTH DAKOTA DEPARTMENT OF HEALTH

# Long Term Care in South Dakota

Providers must continue to follow the [Core Principles of Infection Prevention](#).

- ☀ *Screening (active)*
- ☀ *Hand hygiene*
- ☀ *Face coverings*
- ☀ *Instructional signage and education*
- ☀ *Cleaning and disinfecting*
- ☀ *Appropriate PPE*
- ☀ *Cohorting residents*
- ☀ *Appropriate testing*

## CMS Memos

- [QSO-21-19-NH](#) (revised 5.11.21) - Vaccination
- [QSO-20-38-NH](#) (revised 09.10.21) - Testing
- [QSO-20-39-NH](#) (revised 4.27.21) - Visitation

*This call is not intended for the press or for reporting purposes.*



SOUTH DAKOTA DEPARTMENT OF HEALTH

# Long Term Care in South Dakota


## [QSO-20-38-NH](#) (revised 09.10.21) – Testing

- Revised COVID-19 staff testing is based on the facility's county level of community transmission instead of county test positivity rate.
- Revised the frequency of testing.
- Facilities now have two options to conduct outbreak testing, through either a contact tracing or broad-based testing approach.



## Percent of Current Residents with Completed COVID-19 Vaccinations per Facility

Note: This shows the average percentage among facilities who have reported vaccination data in the current or prior week.



*This call is not intended for the press or for reporting purposes.*




SOUTH DAKOTA DEPARTMENT OF HEALTH



**Choose to get vaccinated. Protect yourself, your family, and our residents.**

## Percent of Current Staff (Healthcare Personnel) with Completed COVID-19 Vaccinations per Facility

Note: This shows the average percentage among facilities who have reported vaccination data in the current or prior week.



*This call is not intended for the press or for reporting purposes.*



SOUTH DAKOTA DEPARTMENT OF HEALTH

# BinaxNOW Testing Kits

To order Sentinel Collection kits from the SDPHL

- Email [SDPHLOrderForm@state.sd.us](mailto:SDPHLOrderForm@state.sd.us)

To start/stop receiving Sentinel Collection kits

- Email [Lori.Konst@state.sd.us](mailto:Lori.Konst@state.sd.us)

To Order Abbott BinaxNow from the Department of Health

- Email [COVIDResourceRequests@state.sd.us](mailto:COVIDResourceRequests@state.sd.us)

*This call is not intended for the press or for reporting purposes.*



SOUTH DAKOTA DEPARTMENT OF HEALTH

# Vaccination Update



SOUTH DAKOTA DEPARTMENT OF HEALTH

# Doses Administered

Total Doses  
Administered\*

794,822

Manufacturer	# of Doses
Janssen	28,518
Moderna	319,684
Pfizer	446,620

Total Persons Administered a  
Vaccine\*

427,298

Doses	# of Recipients
Janssen - Series Complete	28,518
Moderna - 1 dose	11,202
Moderna - Series Complete	154,205
Pfizer - 1 dose	20,681
Pfizer - Series Complete	212,928

Percent of State  
Population with at least  
1 Dose\*\*

65%

Doses	% of Pop.
1 dose	65.00%
Series Complete	59.38%


*Based on 2019 Census Estimate for those  
aged 12+ years.*

*Not intended for press or for reporting purposes.*




SOUTH DAKOTA DEPARTMENT OF HEALTH

## COVID Vaccine coverage by age as of 10/12/2021




# SD DOSES Ordered All Partners



*Not intended for press or for reporting purposes.*

# SD DOSES Ordered All Partners



*Not intended for press or for reporting purposes.*



SOUTH DAKOTA DEPARTMENT OF HEALTH

# SD DOSES Ordered All Partners

1,257,615

Doses Ordered - Total

1,250,455

Doses Shipped - Total

1,240,555

Doses Delivered - Total

732,570

Doses Ordered - Jurisdiction

732,150

Doses Shipped - Jurisdiction

729,080

Doses Delivered - Jurisdiction

Ordered by Pharmacy

Ordered by Federal Entity

348,430

Doses Ordered - Pharmacy

341,690

Doses Shipped - Pharmacy

338,370

Doses Delivered - Pharmacy

176,615

Doses Ordered - Federal Entity

176,615

Doses Shipped - Federal Entity

173,105

Doses Delivered - Federal Entity


*Not intended for press or for reporting purposes.*



SOUTH DAKOTA DEPARTMENT OF HEALTH



D




*Not intended for press or for reporting purposes.*



SOUTH DAKOTA DEPARTMENT OF HEALTH

# Doses Administered by Vaccine



*Not intended for press or for reporting purposes.*



SOUTH DAKOTA DEPARTMENT OF HEALTH

# Coadministration of COVID-19 and Influenza Vaccine

You may administer COVID-19 and influenza vaccines without regard to timing (both live, attenuated and non-live influenza vaccines). This includes administration of COVID-19 and influenza vaccines on the same day, as well as coadministration at any time interval.

With influenza season approaching, there may be compelling logistical advantages to offering patients COVID-19 and influenza vaccines on the same day, and you may encourage patients to receive these on the same day. There are no safety concerns for coadministration.

*Not intended for press or for reporting purposes.*



SOUTH DAKOTA DEPARTMENT OF HEALTH

# Coadministration of COVID-19 and Influenza Vaccine

## **When deciding whether to coadminister another vaccine(s) with COVID-19 vaccine, consider:**

- Whether the patient is behind or at risk of becoming behind on recommended vaccines
- The patient's risk of vaccine-preventable disease
- The reactogenicity profile of the vaccines
- The likelihood of avoiding a missed opportunity to vaccinate

## **Best practices for multiple injections include:**

- Label each syringe with the name and the dosage (amount) of the vaccine, lot number, the initials of the preparer, and the exact beyond-use time, if applicable.
- Separate injection sites by 1 inch or more, if possible.
- Administer the COVID-19 vaccines and vaccines that may be more likely to cause a local reaction (i.e., adjuvanted influenza vaccines) in different limbs, if possible.

## Third dose/Booster Dose

Moderately and Severely immunosuppressed are recommended to get a 3<sup>rd</sup> dose of mRNA vaccine

Persons that should received a Pfizer booster dose:

- Persons aged 65 and older
- Residents aged 18 and older in long term care settings
- Persons 50-64 years with underlying medical conditions

Persons that may received a Pfizer booster dose:

- Persons 18-49 with underlying medical conditions
- Persons 18-64 at increased risk of COVID exposure because of occupational or institutional setting

*Not intended for press or for reporting purposes.*






SOUTH DAKOTA DEPARTMENT OF HEALTH

## Third dose/Booster Dose

- **FDA will meet this week to discuss recommendations for a Moderna booster dose and Janssen booster dose**
  - **Moderna booster dose is expected to be half the normal dose**
- **FDA will meet last week of October to recommend EUA for children to receive Pfizer vaccine.**
  - **Dose anticipated to be 1/3 the amount of antigen of the adult dose.**

# Current and Potential Future Formulations: Product Characteristics

**PRELIMINARY – SUBJECT TO CHANGE PENDING REGULATORY GUIDANCE AND AUTHORIZATION/APPROVAL**

Description	Current Formulation	Future Formulations	
	<i>Dilute Prior to Use</i>	<i>Do Not Dilute</i>	<i>Dilute Prior to Use</i>
Age Group	12 years and older	12 years and older	5 to <12 years*
Vial Cap Color	<b>PURPLE</b> 	<b>GRAY</b> 	<b>ORANGE</b> 
Dose	30 mcg	30 mcg	10 mcg
Injection Volume	0.3 mL	0.3 mL	0.2 mL
Fill Volume (before dilution)	0.45 mL	2.25 mL	1.3 mL
Amount of Diluent* Needed per Vial	1.8 mL	<b>NO DILUTION</b>	1.3 mL
Doses per Vial	6 doses per vial (after dilution)	6 doses per vial	10 doses per vial (after dilution)
<b>Storage Conditions</b>			
ULT Freezer (-90°C to -60°C)	9 months	6 months	6 months
Freezer (-25°C to -15°C)	2 weeks	<b>N/A</b>	<b>N/A</b>
Refrigerator (2°C to 8°C)	1 month	10 weeks	10 weeks

\*Diluent: 0.9% Sodium Chloride Injection, USP

*Not intended for press or for reporting purposes.*



SOUTH DAKOTA DEPARTMENT OF HEALTH

# Infection Prevention



SOUTH DAKOTA DEPARTMENT OF HEALTH



# Infection Control Guidance for Healthcare Facilities: Recent Updates **Sept. 2021**



- [Strategies for Optimizing the Supply of N95 Respirators](#) (Updated 9/16/21)
- [Strategies for Optimizing the Supply of Eye Protection](#) (Updated 9/13/21)
- [CMS Memo: Additional Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency related to Long-Term Care \(LTC\) Facility Testing Requirements](#) (Updated 9/10/21)
- [Interim Infection Prevention and Control Recommendations to Prevent SARS-CoV-2 Spread in Nursing Homes](#) (Updated 9/10/21)
- [Interim Guidance for Managing Healthcare Personnel with SARS-CoV-2 Infection or Exposure to SARS-CoV-2](#) (Updated 9/10/21)
- [Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 \(COVID-19\) Pandemic](#) (Updated 9/10/21)
- [What's New & Updated](#)





## **South Dakota Project Firstline is LIVE! Check Out the Website:**

<https://www.sdprojectfirstline.org>

- \*Training modules
- \*Videos
- \*Brochures and printouts
- \*Contact information for training opportunities for your facility

Additional infection control topics and videos can be found at:  
<https://www.cdc.gov/infectioncontrol/projectfirstline/index.html>



# Additional Educational Resources



**Statewide Program for Infection Control and Epidemiology**

*Education to prevent and control healthcare associated infections across the healthcare spectrum*

<https://spice.unc.edu/webinars/>

\*Recorded webinars on a variety  
of infection control topics



SOUTH DAKOTA DEPARTMENT OF HEALTH

Infection Control Questions? Contact Us:

Kipp Stahl [kipp.stahl@state.sd.us](mailto:kipp.stahl@state.sd.us)

Leah Bomesberger [leah.bomesberger@state.sd.us](mailto:leah.bomesberger@state.sd.us)




SOUTH DAKOTA DEPARTMENT OF HEALTH

# Community Mitigation

New Confirmed Cases	New Probable Cases	Active Cases	Recovered Cases	Currently Hospitalized
9	3	221	122,070	38

### Community Spread Map by County of Residence



Total Confirmed Cases	Total Probable Cases	PCR Test Positivity Rate, Last 1 Day	Total Persons Tested	Total Tests
109,012	15,302	1.7% 06/07/2021	483,192	1,242,936
Ever Hospitalized	Deaths Among Cases	% Progress (April Goal: 44233 Tests)	% Progress (May Goal: 44233 Tests)	% Progress (June Goal: 44233 Tests)
7,107	2,023	228%	134%	22%

# Dashboard


### County

All

PCR Test Positivity Rate, Last 1 Day	PCR Test Positivity Rate, Last 7 Days	PCR Test Positivity Rate, Last 14 Days	PCR Test Positivity Rate, Cumulative
1.7% 06/07/2021	1.9% 6/1/2021 - 6/7/2021	2.5% 5/25/2021 - 6/7/2021	13.4% 3/10/2020 - 6/7/2021

**PCR Test Positivity Rate:** This rate is equal to the number of positive PCR tests divided by total PCR tests, within the specified period of time. Date range includes last full day (24 hours) captured in the data set.

### Confirmed Cases and 14-Day Trend Line by Date Reported to SD-DOH



**14-Day Trend of Confirmed Cases by Date Reported to SD-DOH:** This graph shows the trend (increasing or decreasing) of COVID-19 confirmed cases (persons who meet the national surveillance case definition case for COVID-19) at the state or county level.

Daily Rate of Total Cases, Last 7 Days 6/1/2021 - 6/7/2021	Rate of Total Cases, Cumulative 3/10/2020 - 6/7/2021
1.54 Daily Case Rate per Capita	14,090 Case Rate per Capita

# Supply Chain Management



SOUTH DAKOTA DEPARTMENT OF HEALTH

# PPE Request Procedure

All requests for PPE from DOH must be:

- Emailed to [COVIDResourceRequests@state.sd.us](mailto:COVIDResourceRequests@state.sd.us),
- Faxed to **605.773.5942**, or
- Called in to **605.773.3048** to ensure prioritization and coordination of requests.
- Do not duplicate your request by using all three means of communication.
- Any requests received through any other email or number will all be directed to email [COVIDResourceRequests@state.sd.us](mailto:COVIDResourceRequests@state.sd.us) OR call **605.773.3048** and requesting entities must provide information regarding their current facility status.





# On-going Communication



SOUTH DAKOTA DEPARTMENT OF HEALTH

# Helpful sources of information:

[covid.sd.gov](https://covid.sd.gov)

[coronavirus.gov](https://coronavirus.gov)

- **SD COVID-19 Help Line: 800-997-2880**

SOUTH DAKOTA  
**COVID-19 INFORMATION LINE**  
Questions about COVID-19? We're here to help.  
PLEASE CALL **1-800-997-2880**



SOUTH DAKOTA DEPARTMENT OF HEALTH

# Communications

- SD-HAN: [sdhan.sd.gov](https://sdhan.sd.gov)
- [Epi Listserv](#)
- [Lab Listserv](#)
- [HAI Listserv](#)
- [OLC Listserv](#)

Visit **covid.sd.gov** to subscribe

SOUTH DAKOTA  
**COVID-19 INFORMATION LINE**

Questions about COVID-19? We're here to help.

PLEASE  
CALL **1-800-997-2880**



SOUTH DAKOTA DEPARTMENT OF HEALTH

# Questions?

## Follow-up after the webinar

**COVID Helpline: 800-997-2880**

**Epidemiology: 605-773-3737**

**Laboratory: 605-773-3368**

**[COVID.sd.gov](https://COVID.sd.gov)**

**COVIDSD@state.sd.us**



SOUTH DAKOTA DEPARTMENT OF HEALTH